Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +19 vs. previous quarter
- 291
- 13F valueReported value at the end of Q2 2026
- $2.81B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GMAB, Q2 2026
No superinvestor reported holding GMAB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Genmab A/S insiders from Form 4, newest first.
No open-market purchases or sales by Genmab A/S insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Genmab A/S at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13,133,131 | $360.8M | 6.76% | +5,165,295+64.8% | Added |
| Orbis Allan Gray Ltd | 11,368,161 | $312.3M | 1.07% | −1,557,417−12.0% | Reduced |
| Alliancebernstein L.P. | 8,644,877 | $231.9M | 0.08% | −912,272−9.5% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 6,865,000 | $188.6M | 1.97% | +4,403,000+178.8% | Added |
| Deep Track Capital, LP | 5,650,000 | $155.2M | 2.29% | +1,986,750+54.2% | Added |
| Arrowstreet Capital, Limited Partnership | 4,975,324 | $136.7M | 0.06% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,671,252 | $128.3M | 0.00% | +134,687+3.0% | Added |
| Sofinnova Investments, Inc. | 4,045,215 | $111.1M | 5.94% | +3,292,954+437.7% | Added |
| Renaissance Technologies LLC | 3,517,850 | $96.6M | 0.13% | −896,700−20.3% | Reduced |
| Two Sigma Investments, LP | 3,506,843 | $96.3M | 0.07% | +1,167,411+49.9% | Added |